bluuebunny/crossref_metadata_2025 huggingface dataset:
Selection of EVs as Tourist and Logistic Means of Transportation in Bosnia and Herzegovina’s Nature Protected Areas Using Z-Number and Rough Set Modeling
Authors: Puška Adis , Štilić Anđelka , Božanić Darko , Đurić Aleksandar , Marinkovic Dragan
Published: November 2023

This research focuses on the use of electric vehicles (EVs) to transport visitors and cargo within Bosnia and Herzegovina’s Kozara National Park. Reduced air pollution and the preservation of natural resources are required to help protect this aerial spa. Together with the expert employees of this NP, the EV that would best suit their needs was chosen. The process of decision-making combines subjective and objective methods. Employees first chose the criteria and alternatives and then weighed their importance. On that occasion, Z-numbers were used to include uncertainty in the decision, because it is not always possible to make decisions with complete certainty. Furthermore, the weight of these criteria was determined using the fuzzy PIPRECIA (PIvot Pairwise Relative Criteria Importance Assessment) method. Range (C1) became the most important criterion, followed by vehicle cost (C2), and the technical specifications of these EVs were used to compare them. Because these specifications vary, a rough set was used in which the minimum and maximum EV characteristics were taken based on specific criteria. To rank the alternatives, the R-CRADIS (Rough Compromise Ranking of Alternatives with Distance to Ideal Solution) method was used. According to the research results, the Mercedes eVito Tourer 90 kWh is the highest ranked EV and the validation of the results confirmed these findings. According to the research results, the Mercedes eVito Tourer 90 kWh is the highest ranked EV and the validation of the results confirmed these findings. The sensitivity analysis revealed that if criterion C1 is not as important, the other EVs are ranked higher. This research`s methodology has demonstrated flexibility, therefore it is recommended for use in similar research.
Evaluating the Connectivity and Imbalance Contribution of New Sections towards Highway Network: A Complex Network Perspective
Authors: Wen Zhiyong , Weng Xiaoxiong , Zhang Pengfei
Published: November 2023

The evaluation of the impacts of new sections on the highway network is an essential aspect of the feasibility study. Existing studies predominantly concentrated on engineering-oriented feasibility assessments, often overlooking their potential effects on parallel sections and the overall network. In this research, we present an evaluation model for new sections based on complex networks, focusing on the connectivity and imbalance of transportation networks. This model serves as a supplementary approach for enhancing the feasibility analysis of new highway projects. The model comprises three distinct modules, namely, complex network, eigenvalue, and evaluation. Therein, the complex network provides diverse attributes for sections with the dynamic edge weights. Moreover, probability betweenness centrality and volume betweenness centrality have been presented as an eigenvalue of sections based on the multilayer complex network. Furthermore, the connectivity evaluation based on the eigenvalue and the imbalance evaluation based on the entropy and Gini coefficient are conducted. Through the case study, the results of the model demonstrate the connectivity and imbalance contribution of new sections and provide a novel perspective for the feasibility study.
A Cross‐Sectional Study of Myopia and Morning Melatonin Status in Northern Irish Adolescent Children
Authors: Fulton Jane M. , Flanagan Sarah C. , Sittlington Julie J. , Cobice Diego , Dobbin Sara , McCullough Sara J. , Orr Gareth , Richardson Patrick , Saunders Kathryn J.
Published: November 2023

Purpose. Previous studies have demonstrated an association between melatonin status and both refractive error and axial length in young adult myopes. This study aimed to determine if this relationship extends to a younger adolescent cohort. Methods. Healthy children aged 12–15 years provided morning saliva samples before attending Ulster University (55°N) for cycloplegic autorefraction and axial length measures. Participants completed questionnaires describing recent sleep habits and physical activity. Salivary melatonin was quantified using high‐performance liquid chromatography‐tandem mass spectrometry. Data collection for all participants occurred over a 1‐week period (April 2021). Results. Seventy participants aged 14.3 (95% CI: 14.2—14.5) years were categorised by spherical equivalent refraction [SER] (range: −5.38DS to +1.88DS) into two groups; myopic SER ≤ −0.50DS (n = 22) or nonmyopic −0.50DS < SER ≤ +2.00DS (n = 48). Median morning salivary melatonin levels were 4.52 pg/ml (95% CI: 2.60–6.02) and 4.89 pg/ml (95% CI: 3.18–5.66) for myopic and nonmyopic subjects, respectively, and did not differ significantly between refractive groups (P = 0.91). Melatonin levels were not significantly correlated with SER, axial length, sleep, or activity scores (Spearman’s rank, all P > 0.39). Higher levels of physical activity were associated with higher sleep quality (Spearman’s rank, ρ = −0.28, P = 0.02). Conclusion. The present study found no significant relationship between morning salivary melatonin levels and refractive error or axial length in young adolescents. This contrasts with outcomes from a previous study of adults with comparable methodology, season of data collection, and geographical location. Prospective studies are needed to understand the discrepancies between adult and childhood findings and evaluate whether melatonin levels in childhood are indicative of an increased risk for future onset of myopia and/or faster axial growth trajectories and myopia progression in established myopes. Future work should opt for a comprehensive dim‐light melatonin onset protocol to determine circadian phase.
Supplementary Figure Legends from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
Authors: Perales-Linares Renzo , Leli Nektaria Maria , Mohei Hesham , Beghi Silvia , Rivera Osvaldo D. , Kostopoulos Nektarios , Giglio Andrea , George Subin S. , Uribe-Herranz Mireia , Costabile Francesca , Pierini Stefano , Pustylnikov Sergei , Skoufos Giorgos , Barash Yoseph , Hatzigeorgiou Artemis G. , Koumenis Constantinos , Maity Amit , Lotze Michael T. , Facciabene Andrea
Published: November 2023

Supplementary Figure Legends
Supplementary Data from The IGF2BP3–COPS7B Axis Facilitates mRNA Translation to Drive Colorectal Cancer Progression
Authors: Tang Jing , Wang Shuoshuo , Weng Mingjiao , Guo Qingyu , Ren Lili , He Yan , Cui Zihan , Cong Mingqi , Qin Minglu , Yu Jia , Su Rui , Li Xiaobo
Published: November 2023

Supplementary Figures
Supplemental Figure S8 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Authors: Cotton Jennifer L. , Estrada Diez Javier , Sagar Vivek , Chen Julie , Piquet Michelle , Alford John , Song Youngchul , Li Xiaoyan , Riester Markus , DiMare Matthew T. , Schumacher Katja , Boulay Gaylor , Sprouffske Kathleen , Fan Lin , Burks Tyler , Mansur Leandra , Wagner Joel , Bhang Hyo-eun C. , Iartchouk Oleg , Reece-Hoyes John , Morris Erick J. , Hammerman Peter S. , Ruddy David A. , Korn Joshua M. , Engelman Jeffrey A. , Niederst Matthew J.
Published: November 2023

Supplemental Figure S8 shows clone family contribution at drug resistance and sensitivity to drug combinations.
Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Authors: Cotton Jennifer L. , Estrada Diez Javier , Sagar Vivek , Chen Julie , Piquet Michelle , Alford John , Song Youngchul , Li Xiaoyan , Riester Markus , DiMare Matthew T. , Schumacher Katja , Boulay Gaylor , Sprouffske Kathleen , Fan Lin , Burks Tyler , Mansur Leandra , Wagner Joel , Bhang Hyo-eun C. , Iartchouk Oleg , Reece-Hoyes John , Morris Erick J. , Hammerman Peter S. , Ruddy David A. , Korn Joshua M. , Engelman Jeffrey A. , Niederst Matthew J.
Published: November 2023

Supplemental Figure S4 shows abundance of individual barcoded clones.
Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Authors: Cotton Jennifer L. , Estrada Diez Javier , Sagar Vivek , Chen Julie , Piquet Michelle , Alford John , Song Youngchul , Li Xiaoyan , Riester Markus , DiMare Matthew T. , Schumacher Katja , Boulay Gaylor , Sprouffske Kathleen , Fan Lin , Burks Tyler , Mansur Leandra , Wagner Joel , Bhang Hyo-eun C. , Iartchouk Oleg , Reece-Hoyes John , Morris Erick J. , Hammerman Peter S. , Ruddy David A. , Korn Joshua M. , Engelman Jeffrey A. , Niederst Matthew J.
Published: November 2023

Supplemental Figure S3 shows Louvain clusters overlaid onto UMAP plots and contribution of cells by time point.
Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Authors: Cotton Jennifer L. , Estrada Diez Javier , Sagar Vivek , Chen Julie , Piquet Michelle , Alford John , Song Youngchul , Li Xiaoyan , Riester Markus , DiMare Matthew T. , Schumacher Katja , Boulay Gaylor , Sprouffske Kathleen , Fan Lin , Burks Tyler , Mansur Leandra , Wagner Joel , Bhang Hyo-eun C. , Iartchouk Oleg , Reece-Hoyes John , Morris Erick J. , Hammerman Peter S. , Ruddy David A. , Korn Joshua M. , Engelman Jeffrey A. , Niederst Matthew J.
Published: November 2023

Supplemental Figure S1 shows barcode enrichment in drug treated cells, copy number segmentation, and xBC library cloning.
Table S2 from Matrix Stiffness Triggers Lipid Metabolic Cross-talk between Tumor and Stromal Cells to Mediate Bevacizumab Resistance in Colorectal Cancer Liver Metastases
Authors: Zheng Yannan , Zhou Rui , Cai Jianan , Yang Nanyan , Wen Zhaowei , Zhang Zhihua , Sun Huiying , Huang Genjie , Guan Yijin , Huang Na , Shi Min , Liao Yulin , Bin Jianping , Liao Wangjun
Published: November 2023

Supplementary Table S2. The composition of polyacrylamide gels
Table S8 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
Authors: Chen Zhihang , Zhang Guopei , Ren Xiaoxue , Yao Zhijia , Zhou Qian , Ren Xuxin , Chen Shuling , Xu Lixia , Sun Kaiyu , Zeng Qianwen , Kuang Ming , Kuang Dong-Ming , Peng Sui
Published: November 2023

Table S8
Table S7 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
Authors: Chen Zhihang , Zhang Guopei , Ren Xiaoxue , Yao Zhijia , Zhou Qian , Ren Xuxin , Chen Shuling , Xu Lixia , Sun Kaiyu , Zeng Qianwen , Kuang Ming , Kuang Dong-Ming , Peng Sui
Published: November 2023

Table S7
Supplementary figures from DNA Methylation-Based Testing in Peripheral Blood Mononuclear Cells Enables Accurate and Early Detection of Colorectal Cancer
Authors: Xie Yan , Li Peilong , Sun Dong , Qi Qiuchen , Ma Suhong , Zhao Yinghui , Zhang Shujun , Wang Tiantian , Wang Jing , Li Shijun , Gong Tingting , Xu Huiting , Xiong Mengqiu , Li Guanghua , You Chongge , Luo Zhaofan , Li Juan , Wang Chuanxin , Du Lutao
Published: November 2023

Supplementary figures
Table S4 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
Authors: Chen Zhihang , Zhang Guopei , Ren Xiaoxue , Yao Zhijia , Zhou Qian , Ren Xuxin , Chen Shuling , Xu Lixia , Sun Kaiyu , Zeng Qianwen , Kuang Ming , Kuang Dong-Ming , Peng Sui
Published: November 2023

Table S4
Figure S9 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
Authors: Chen Zhihang , Zhang Guopei , Ren Xiaoxue , Yao Zhijia , Zhou Qian , Ren Xuxin , Chen Shuling , Xu Lixia , Sun Kaiyu , Zeng Qianwen , Kuang Ming , Kuang Dong-Ming , Peng Sui
Published: November 2023

Figure S9
Data from Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib
Authors: Zeng Xiangyu , Zhao Fei , Jia Jie , Ma Xianxiong , Jiang Qi , Zhang Ruizhi , Li Chengguo , Wang Tao , Liu Weizhen , Hao Yalan , Tao Kaixiong , Lou Zhenkun , Zhang Peng
Published: November 2023

Abstract
Imatinib mesylate (IM) has revolutionized the treatment of gastrointestinal stromal tumor (GIST). However, most patients inevitably acquire IM resistance. Second- and third-line treatments exhibit modest clinical benefits with a median time to disease progression of 4 to 6 months, highlighting the urgency for novel therapeutic approaches. Here, we report that the expression of BCL6, a known oncogenic driver and transcriptional repressor, was significantly induced in GIST cells following IM treatment. Elevated BCL6 levels suppressed apoptosis and contributed to IM resistance. Mechanistically, BCL6 recruited SIRT1 to the TP53 promoter to modulate histone acetylation and transcriptionally repress TP53 expression. The reduction in p53 subsequently attenuated cell apoptosis and promoted tolerance of GIST cells to IM. Concordantly, treatment of GIST cells showing high BCL6 expression with a BCL6 inhibitor, BI-3802, conferred IM sensitivity. Furthermore, BI-3802 showed striking synergy with IM in IM-responsive and IM-resistant GIST cells in vitro and in vivo. Thus, these findings reveal a role for BCL6 in IM resistance and suggest that a combination of BCL6 inhibitors and IM could be a potentially effective treatment for GIST.
Significance:
BCL6 drives resistance to imatinib by inhibiting p53-mediated apoptosis and can be targeted in combination with imatinib to synergistically suppress tumor growth, providing a therapeutic strategy for treating gastrointestinal stromal tumor.
Data from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Authors: Cotton Jennifer L. , Estrada Diez Javier , Sagar Vivek , Chen Julie , Piquet Michelle , Alford John , Song Youngchul , Li Xiaoyan , Riester Markus , DiMare Matthew T. , Schumacher Katja , Boulay Gaylor , Sprouffske Kathleen , Fan Lin , Burks Tyler , Mansur Leandra , Wagner Joel , Bhang Hyo-eun C. , Iartchouk Oleg , Reece-Hoyes John , Morris Erick J. , Hammerman Peter S. , Ruddy David A. , Korn Joshua M. , Engelman Jeffrey A. , Niederst Matthew J.
Published: November 2023

Abstract
For a majority of patients with non–small cell lung cancer with EGFR mutations, treatment with EGFR inhibitors (EGFRi) induces a clinical response. Despite this initial reduction in tumor size, residual disease persists that leads to disease relapse. Elucidating the preexisting biological differences between sensitive cells and surviving drug-tolerant persister cells and deciphering how drug-tolerant cells evolve in response to treatment could help identify strategies to improve the efficacy of EGFRi. In this study, we tracked the origins and clonal evolution of drug-tolerant cells at a high resolution by using an expressed barcoding system coupled with single-cell RNA sequencing. This platform enabled longitudinal profiling of gene expression and drug sensitivity in response to EGFRi across a large number of clones. Drug-tolerant cells had higher expression of key survival pathways such as YAP and EMT at baseline and could also differentially adapt their gene expression following EGFRi treatment compared with sensitive cells. In addition, drug combinations targeting common downstream components (MAPK) or orthogonal factors (chemotherapy) showed greater efficacy than EGFRi alone, which is attributable to broader targeting of the heterogeneous EGFRi-tolerance mechanisms present in tumors. Overall, this approach facilitates thorough examination of clonal evolution in response to therapy that could inform the development of improved diagnostic approaches and treatment strategies for targeting drug-tolerant cells.
Significance:
The evolution and heterogeneity of EGFR inhibitor tolerance are identified in a large number of clones at enhanced cellular and temporal resolution using an expressed barcode technology coupled with single-cell RNA sequencing.
Data from Fasting-Mimicking Diet Drives Antitumor Immunity against Colorectal Cancer by Reducing IgA-Producing Cells
Authors: Zhong Ziwen , Zhang Hao , Nan Ke , Zhong Jing , Wu Qichao , Lu Lihong , Yue Ying , Zhang Zhenyu , Guo Miaomiao , Wang Zhiqiang , Xia Jie , Xing Yun , Fu Ying , Yu Baichao , Zhou Wenchang , Sun Xingfeng , Shen Yang , Chen Wankun , Zhang Jie , Zhang Jin , Ma Duan , Chu Yiwei , Liu Ronghua , Miao Changhong
Published: November 2023

Abstract
As a safe, feasible, and inexpensive dietary intervention, fasting-mimicking diet (FMD) exhibits excellent antitumor efficacy by regulating metabolism and boosting antitumor immunity. A better understanding of the specific mechanisms underlying the immunoregulatory functions of FMD could help improve and expand the clinical application of FMD-mediated immunotherapeutic strategies. In this study, we aimed to elucidate the role of metabolic reprogramming induced by FMD in activation of antitumor immunity against colorectal cancer. Single-cell RNA sequencing analysis of intratumoral immune cells revealed that tumor-infiltrating IgA+ B cells were significantly reduced by FMD treatment, leading to the activation of antitumor immunity and tumor regression in murine colorectal cancer models. Mechanistically, FMD delayed tumor growth by repressing B-cell class switching to IgA. Therefore, FMD-induced reduction of IgA+ B cells overcame the suppression of CD8+ T cells. The immunoregulatory and antitumor effects of FMD intervention were reversed by IgA+ B-cell transfer. Moreover, FMD boosted fatty acid oxidation (FAO) to trigger RUNX3 acetylation, thus inactivating Cα gene transcription and IgA class switching. IgA+ B-cell expansion was also impeded in patients placed on FMD, while B-cell expression of carnitine palmitoyl transferase 1A (CPT1A), the rate-limiting enzyme of FAO, was increased. Furthermore, CPT1A expression was negatively correlated with both IgA+ B cells and IgA secretion within colorectal cancer. Together, these results highlight that FMD holds great promise for treating colorectal cancer. Furthermore, the degree of IgA+ B cell infiltration and FAO-associated metabolic status are potential biomarkers for evaluating FMD efficacy.
Significance:
Metabolic reprogramming of B cells induced by fasting-mimicking diet suppresses IgA class switching and production to activate antitumor immunity and inhibit tumor growth.

See related commentary by Bush and Perry, p. 3493
Table S2 from Gene–Environment Analyses in a UK Biobank Skin Cancer Cohort Identifies Important SNPs in DNA Repair Genes That May Help Prognosticate Disease Risk
Authors: Jeremian Richie , Xie Pingxing , Fotovati Misha , Lefrançois Philippe , Litvinov Ivan V.
Published: November 2023

Table S2. Ratios corresponding to skin cancer risk for each demographic and environmental variables.
Supplemental Table 1 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Authors: Streck Joanna M. , Lee Ju-Whei , Walter Angela Wangari , Rosen Rachel L. , Gareen Ilana F. , Kircher Sheetal Mehta , Herman Benjamin A. , Carlos Ruth C. , Kumar Shaji , Mayer Ingrid A. , Saba Nabil F. , Fenske Timothy S. , Neal Joel W. , Atkins Michael B. , Hodi F. Stephen , Kyriakopoulos Christos E. , Tempany Clare , Shanafelt Tait D. , Wagner Lynne I. , Land Stephanie R. , Park Elyse R. , Ostroff Jamie S.
Published: November 2023

Supplemental Table 1 shows cancer types, patient accrual and survey completion rates for parent trials
Figure S1 from Gene–Environment Analyses in a UK Biobank Skin Cancer Cohort Identifies Important SNPs in DNA Repair Genes That May Help Prognosticate Disease Risk
Authors: Jeremian Richie , Xie Pingxing , Fotovati Misha , Lefrançois Philippe , Litvinov Ivan V.
Published: November 2023

Figure S1. Waterfall plot highlighting significant (q<0.05) SNP-environment interactions in basal cell carcinoma (BCC). Relationships were computed using a robust joint interaction test and assessed for significance using the False Discovery Rate (FDR) method. These findings demonstrate the importance of several variables, namely sunlamp use and history of childhood sunburns, in interacting with DNA repair genes to mediate the risk of BCC. This figure also highlights BRCA2, DCLRE1B and FANCA as critical genes which interact with nearly every demographic, environmental and behavioral variable.
Supplementary Table S4 from Racial and Ethnic Variation in Diagnostic Mammography Performance among Women Reporting a Breast Lump
Authors: Nyante Sarah J. , Abraham Linn , Aiello Bowles Erin J. , Lee Christoph I. , Kerlikowske Karla , Miglioretti Diana L. , Sprague Brian L. , Henderson Louise M.
Published: November 2023

Model-based comparisons of diagnostic mammography performance by race and ethnicity
Supplementary Table 2 from Long-term Cancer Survival Trends by Updated Summary Stage
Authors: Forjaz Gonçalo , Ries Lynn , Devasia Theresa P. , Flynn Gretchen , Ruhl Jennifer , Mariotto Angela B.
Published: November 2023

Trends in incidence rates for selected cancers by long-term site-specific summary stage, SEER-8, 1975-2019
Supplementary Table S1 from Racial and Ethnic Variation in Diagnostic Mammography Performance among Women Reporting a Breast Lump
Authors: Nyante Sarah J. , Abraham Linn , Aiello Bowles Erin J. , Lee Christoph I. , Kerlikowske Karla , Miglioretti Diana L. , Sprague Brian L. , Henderson Louise M.
Published: November 2023

Raw numbers for performance statistic calculations
Supplementary Table 1 from Do Polygenic Risk Scores Add to Clinical Data in Predicting Pancreatic Cancer? A Scoping Review
Authors: Wang Louise , Grimshaw Alyssa A. , Mezzacappa Catherine , Rahimi Larki Navid , Yang Yu-Xiao , Justice Amy C.
Published: November 2023

Supplementary Table 1 shows the preferred reporting items for systematic reviews and meta-analyses extension for scoping reviews (PRISMA-ScR) checklist
Supplementary Table 3 from Sources of Disparities in Surveillance Mammography Performance and Risk-Guided Recommendations for Supplemental Breast Imaging: A Simulation Study
Authors: Hubbard Rebecca A. , Pujol Toyya A. , Alhajjar Elie , Edoh Kossi , Martin Melissa L.
Published: November 2023

Supplementary Table 3. Sensitivity and cancer risk prediction logistic regression model coefficients
Supplementary Figure 2 from Sources of Disparities in Surveillance Mammography Performance and Risk-Guided Recommendations for Supplemental Breast Imaging: A Simulation Study
Authors: Hubbard Rebecca A. , Pujol Toyya A. , Alhajjar Elie , Edoh Kossi , Martin Melissa L.
Published: November 2023

Supplementary Figure 2. Simulation results for surveillance mammography cancer detection rates overall and stratified by race and ethnicity in simulated populations of women with a personal history of breast cancer
Supplementary Figure 1 from Sources of Disparities in Surveillance Mammography Performance and Risk-Guided Recommendations for Supplemental Breast Imaging: A Simulation Study
Authors: Hubbard Rebecca A. , Pujol Toyya A. , Alhajjar Elie , Edoh Kossi , Martin Melissa L.
Published: November 2023

Supplementary Figure 1. Simulation results for surveillance mammography false-negative rates overall and stratified by race and ethnicity in simulated populations of women with a personal history of breast cancer
Supplementary Table S1 from Reproductive Factors in the Risk of Bladder Cancer and Upper Urinary Tract Cancer: The Japan Public Health Center-Based Prospective Study
Authors: Minami Tetsuji , Inoue Manami , Yamaji Taiki , Iwasaki Motoki , Tsugane Shoichiro , Sawada Norie
Published: November 2023

Supplementary Table S1: Characteristics among menopause without details and unknown menopausal status.
Data from Impact on the Volume of Pathology Reports Before and During the COVID-19 Pandemic in SEER Cancer Registries
Authors: Chtourou Amina , Sanchez Pamela V. , Golden Todd , Chen Huann-Sheng , Schwartz Stephen M. , Wu Xiao-Cheng , Hernandez Brenda Y. , Harrison Jovanka N. , Penberthy Lynne , Negoita Serban
Published: November 2023

AbstractIntroduction:
Health care procedures including cancer screening and diagnosis were interrupted due to the COVID-19 pandemic. The extent of this impact on cancer care in the United States is not fully understood. We investigated pathology report volume as a reflection of trends in oncology services pre-pandemic and during the pandemic.
Methods:
Electronic pathology reports were obtained from 11 U.S. central cancer registries from NCI's SEER Program. The reports were sorted by cancer site and document type using a validated algorithm. Joinpoint regression was used to model temporal trends from January 2018 to February 2020, project expected counts from March 2020 to February 2021 and calculate observed-to-expected ratios. Results were stratified by sex, age, cancer site, and report type.
Results:
During the first 3 months of the pandemic, pathology report volume decreased by 25.5% and 17.4% for biopsy and surgery reports, respectively. The 12-month O/E ratio (March 2020–February 2021) was lowest for women (O/E 0.90) and patients 65 years and older (O/E 0.91) and lower for cancers with screening (melanoma skin, O/E 0.86; breast, O/E 0.88; lung O/E 0.89, prostate, O/E 0.90; colorectal, O/E 0.91) when compared with all other cancers combined.
Conclusions:
These findings indicate a decrease in cancer diagnosis, likely due to the COVID-19 pandemic. This decrease in the number of pathology reports may result in a stage shift causing a subsequent longer-term impact on survival patterns.
Impact:
Investigation on the longer-term impact of the pandemic on pathology services is vital to understand if cancer care delivery levels continue to be affected.
Data from Gene–Environment Analyses in a UK Biobank Skin Cancer Cohort Identifies Important SNPs in DNA Repair Genes That May Help Prognosticate Disease Risk
Authors: Jeremian Richie , Xie Pingxing , Fotovati Misha , Lefrançois Philippe , Litvinov Ivan V.
Published: November 2023

AbstractBackground:
Despite well-established relationships between sun exposure and skin cancer pathogenesis/progression, specific gene–environment interactions in at-risk individuals remain poorly-understood.
Methods:
We leveraged a UK Biobank cohort of basal cell carcinoma (BCC, n = 17,221), cutaneous squamous cell carcinoma (cSCC, n = 2,331), melanoma in situ (M-is, n = 1,158), invasive melanoma (M-inv, n = 3,798), and healthy controls (n = 448,164) to quantify the synergistic involvement of genetic and environmental factors influencing disease risk. We surveyed 8,798 SNPs from 190 DNA repair genes, and 11 demographic/behavioral risk factors.
Results:
Clinical analysis identified darker skin (RR = 0.01–0.65) and hair (RR = 0.27–0.63) colors as protective factors. Eleven SNPs were significantly associated with BCC, three of which were also associated with M-inv. Gene–environment analysis yielded 201 SNP–environment interactions across 90 genes (FDR-adjusted q < 0.05). SNPs from the FANCA gene showed interactions with at least one clinical factor in all cancer groups, of which three (rs9926296, rs3743860, rs2376883) showed interaction with nearly every factor in BCC and M-inv.
Conclusions:
We identified novel risk factors for keratinocyte carcinomas and melanoma, highlighted the prognostic value of several FANCA alleles among individuals with a history of sunlamp use and childhood sunburns, and demonstrated the importance of combining genetic and clinical data in disease risk stratification.
Impact:
This study revealed genome-wide associations with important implications for understanding skin cancer risk in the context of the rapidly-evolving field of precision medicine. Major individual factors (including sex, hair and skin color, and sun protection use) were significant mediators for all skin cancers, interacting with >200 SNPs across four skin cancer types.
Data from Administrative Burden Associated with Cost-Related Delays in Care in U.S. Cancer Patients
Authors: Doherty Meredith , Thom Bridgette , Gardner Daniel S.
Published: November 2023

AbstractBackground:
U.S. cancer patients engage in administrative tasks to pay for their healthcare. This study investigated the relationship between payment tasks and timely access to cancer care.
Methods:
We analyzed online survey data from 510 U.S. cancer patients and survivors to understand the relationship between administrative payment tasks and cost-related delays and nonadherence. Two-part modelling was used to determine if, and to what extent, there was a relationship between administrative burden and cost-related delays/nonadherence.
Results:
Younger patients (≤44 years) reported more payment tasks and cost-related delays/nonadherence than older patients (≥ 55 years); African American patients reported more payment tasks and cost-related delays/nonadherence than white patients. After accounting for age, race/ethnicity, education, and out-of-pocket costs, patients who reported engaging in more tasks had greater log odds of delaying/forgoing care [b = 0.18; 95% confidence interval (CI), 0.12–0.24]. Cost-related delays/nonadherence increased by 32% for every unit increase in administrative payment burden (b = 0.32; 95% CI, 0.18–0.46).
Conclusions:
Administrative payment burden increased the odds of cost-related delays and nonadherence by 49%, taking the form of delayed or skipped doctor appointments, tests and bloodwork, and prescription fulfillment. Younger patients and those identifying as African American were more likely to engage in payment tasks and to delay or forgo care due to cost. Administrative burdens can disrupt access to care and traditionally underserved patient populations are disproportionately exposed to these hardships.
Impact:
Reducing the complexity of healthcare through universal, human-centered design could reduce burdens and increase access.
Supplementary Table S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

The Supplementary table "Representativeness of Study Participants" reports several comments regarding the representativeness of study participants including age, geography and overall representativeness of the study.
Supplementary Methods S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

supplementary methods
Supplementary Figure S4 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

Oncogenetic trees in patients with baseline tumors and resistant samples
Supplementary Figure S3 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

Genomic landscape of the whole cohort
Supplemental Figure S3 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Authors: McKay-Corkum Grace B. , Collins Victor J. , Yeung Choh , Ito Takeshi , Issaq Sameer H. , Holland David , Vulikh Ksenia , Zhang Yiping , Lee Unsun , Lei Haiyan , Mendoza Arnulfo , Shern Jack F. , Yohe Marielle E. , Yamamoto Kazutoshi , Wilson Kelli , Ji Jiuping , Karim Baktiar O. , Thomas Craig J. , Krishna Murali C. , Neckers Leonard M. , Heske Christine M.
Published: November 2023

Supplemental Figure S3: Effects of OT-82 on RMS energy metabolism
Supplementary Table S4 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Authors: Drakaki Alexandra , Powles Thomas , Bamias Aristotelis , Martin-Liberal Juan , Shin Sang Joon , Friedlander Terence , Tosi Diego , Park Chandler , Gomez-Roca Carlos , Joly Lobbedez Florence , Castellano Daniel , Morales-Barrera Rafael , Moreno-Candilejo Irene , Fléchon Aude , Yuen Kobe , Rishipathak Deepali , DuPree Kelly , Young Fiona , Michielin Francesca , Shemesh Colby S. , Steinberg Elizabeth E. , Williams Patrick , Lee Jae Lyun
Published: November 2023

Supplementary Table 4. Adverse events leading to any treatment discontinuation.
Supplementary Data S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

The supplementary Data 1 describes the clinical characteristics of patients included in the analysis.
Supplementary Table S1 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Table S1. Specification of reagents for flow cytometry (Whole Blood Assay)
Supplementary Method S1 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Methods
Supplementary Figure S9 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Figure S9. Single cell RNA-sequencing of whole blood treated with 0.2 μg/mL CD20-TCB was performed using the BD Rhapsody platform
Supplementary Figure S6 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Figure S6. A. Bulk-rna-sequencing of neutrophils purified from whole blood 4 hrs and 20 hrs following treatment with 0.2 μg/mL CD20-TCB or 0.2 μg/mL DP47-TCB for N=4 donors. B. Heat map showing the enriched hallmark pathways in neutrophils, 4 hrs and 20 hrs following treatment with CD20-TCB or DP47-TCB. C. Heat map showing the expression of TNF-α (TNF), IL-1β (IL1B), IL-6 (IL6), MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4) and IP-10 (CXCL10) genes in neutrophils, 4 hrs and 20 hrs following treatment with CD20-TCB or DP47-TCB (untargeted TCB). Volcano plots depicting the cytokine genes in neutrophils D. 4 hrs and E. 20 hrs after treatment with CD20-TCB. Each dot represents one gene. The x axis shows the logarithmic fold change and the y axis shows the negative log of the p value for each gene by comparing samples treated with CD20-TCB to samples treated with DP47-TCB (untargeted TCB).
Supplementary Table S6 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Table S6. Gene set enrichment analysis using the KEGG pathways and Gene Ontology Biological Processes databases. Pathways statistically significant activated or suppressed after twelve months exercise are displayed (BH-adjusted P-value<0.05).
Supplementary Table S5 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Table S5. Results of differential gene expression analysis between the exercise and usual care groups using mRNAseq.
Supplementary Figure S4 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Figure S4. Multidimensional scaling plot of gene expression distances between pseudobulks
Supplementary Figure S3 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Figure S3. Identification of an interacting B and T cells cluster by scRNA sequencing of human whole blood treated with 0.2 μg/mL CD20-TCB using the BD Rhapsody platform.
Supplementary Figure S2 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Figure S2. Proportions of T cells, monocytes and neutrophils in human whole blood after treatment with 0.2 μg/mL CD20-TCB
Supplementary Materials and Methods 1 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Supplementary Materials and Methods
Supplementary Figure S4 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Figure S4. Relative change in prostaglandin metabolite levels after twelve months follow-up in usual care and exercise groups (A-C, Wilcoxon signed-rank test; ns, P>0.05; *, P ≤0.05; **, P≤0.01).
Figure S1 from Circulating microRNAs and Cytokines as Prognostic Biomarkers for Doxorubicin-Induced Cardiac Injury and for Evaluating the Effectiveness of an Exercise Intervention
Authors: Jeyabal Prince , Bhagat Anchit , Wang Fei , Roth Michael , Livingston J. Andrew , Gilchrist Susan C. , Banchs Jose , Hildebrandt Michelle A.T. , Chandra Joya , Deswal Anita , Koutroumpakis Efstratios , Wang Jian , Daw Najat C. , Honey Theresa A. , Kleinerman Eugenie S.
Published: November 2023

Figure S1
Supplementary Table S4 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
Authors: Casanova Michela , Bautista Francisco , Campbell-Hewson Quentin , Makin Guy , Marshall Lynley V. , Verschuur Arnauld C. , Cañete Nieto Adela , Corradini Nadège , Ploeger Bart A. , Brennan Barbara J. , Mueller Udo , Zebger-Gong Hong , Chung John W. , Geoerger Birgit
Published: November 2023

Table of dose-limiting toxicities
Supplementary Table S1 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
Authors: Casanova Michela , Bautista Francisco , Campbell-Hewson Quentin , Makin Guy , Marshall Lynley V. , Verschuur Arnauld C. , Cañete Nieto Adela , Corradini Nadège , Ploeger Bart A. , Brennan Barbara J. , Mueller Udo , Zebger-Gong Hong , Chung John W. , Geoerger Birgit
Published: November 2023

Table showing treatment-emergent adverse events
Supplementary Figure S4 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
Authors: Casanova Michela , Bautista Francisco , Campbell-Hewson Quentin , Makin Guy , Marshall Lynley V. , Verschuur Arnauld C. , Cañete Nieto Adela , Corradini Nadège , Ploeger Bart A. , Brennan Barbara J. , Mueller Udo , Zebger-Gong Hong , Chung John W. , Geoerger Birgit
Published: November 2023

Distribution of the median clearance of irinotecan and its active metabolite (SN-38) derived from the published variability distribution of the clearances versus the estimated median clearance of irinotecan and SN-38 in this study.
Supplementary Table S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Thummalapalli Rohit , Ricciuti Biagio , Bandlamudi Chaitanya , Muldoon Daniel , Rizvi Hira , Elkrief Arielle , Luo Jia , Alessi Joao V. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Hong Lingzhi , Zhang Jianjun , Heymach John V. , Gibbons Don L. , Plodkowski Andrew J. , Ravichandran Vignesh , Donoghue Mark T.A. , Vanderbilt Chad , Ladanyi Marc , Rudin Charles M. , Kris Mark G. , Riely Gregory J. , Chaft Jamie E. , Hellmann Matthew D. , Vokes Natalie I. , Awad Mark M. , Schoenfeld Adam J.
Published: November 2023

List of 301 genes included in all versions of MSK-IMPACT and DFCI OncoPanel NGS platforms used for all analyses.
Supplementary Figure S1 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
Authors: Casanova Michela , Bautista Francisco , Campbell-Hewson Quentin , Makin Guy , Marshall Lynley V. , Verschuur Arnauld C. , Cañete Nieto Adela , Corradini Nadège , Ploeger Bart A. , Brennan Barbara J. , Mueller Udo , Zebger-Gong Hong , Chung John W. , Geoerger Birgit
Published: November 2023

Chart showing treatment schema.